LONG MINI-FUTURE - GENMAB | Real-time Bid/Ask 05:44:32 23/05/2024 pm IST | ||
| 16.42 EUR / 16.44 EUR | +7.81% |
|
| Current month | -1.87% | ||
| 1 month | -4.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 23/24/23 | 16.14 | +5.91% |
| 22/24/22 | 15.24 | -3.61% |
| 21/24/21 | 15.81 | -0.13% |
| 17/24/17 | 15.83 | -2.22% |
| 16/24/16 | 16.19 | +3.12% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 12:19 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA8XDD |
| ISIN | DE000VA8XDD5 |
| Date issued | 26/10/2018 |
| Strike | 840.8 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.67 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.14 € |
|---|---|
| Lowest since issue | 1.97 € |
| Spread | 0.02 € |
| Spread % | 0.12% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,055
DKK
Average target price
2,466
DKK
Spread / Average Target
+19.99%
- Stock Market
- Certificates
- Certificat
